We are live on ! Find out more
SMMT icon

Summit Therapeutics
SMMT

8 hedge funds and large institutions have $33.2M invested in Summit Therapeutics in 2015 Q1 according to their latest regulatory filings, with 8 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
8
Holders Change
+8
Holders Change %
–
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
LPU
Lansdowne Partners (UK)
United Kingdom
+$10.5M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$9.55M
3
Axa
Axa
France
+$3.32M
4
First Eagle Investment Management
First Eagle Investment Management
New York
+$1.98M
5
SFM
Sphera Funds Management
Israel
+$1.98M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
LPU
1
Lansdowne Partners (UK)
United Kingdom
$11.5M +$10.5M +930,000 New
Point72 Asset Management
2
Point72 Asset Management
Connecticut
$10.4M +$9.55M +843,300 New
Axa
3
Axa
France
$3.63M +$3.32M +292,907 New
First Eagle Investment Management
4
First Eagle Investment Management
New York
$2.17M +$1.98M +175,000 New
SFM
5
Sphera Funds Management
Israel
$2.17M +$1.98M +175,000 New
Janus Henderson Group
6
Janus Henderson Group
United Kingdom
$1.72M +$1.58M +139,166 New
GPCM
7
Granite Point Capital Management
Massachusetts
$1.55M +$1.42M +125,000 New
TRCT
8
Tower Research Capital (TRC)
New York
– +$57 +5 New

SMMT Hedge Fund Activity: Q1 2015 in Review

8 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q1 2015, worth a combined $33.2M.

Buyers outnumbered sellers: 8 funds opened new SMMT positions and 0 closed out — a net gain of 8 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Lansdowne Partners (UK), opening a new position worth an estimated $10.5M.

  • 8 institutional investors held Summit Therapeutics (SMMT) as of Q1 2015, up from 0 in Q4 2014.
  • Funds reported $33.2M of Summit Therapeutics stock for Q1 2015.
  • 8 funds opened new Summit Therapeutics positions in Q1 2015 and 0 closed out, a net change of +8 holders.
  • The largest Summit Therapeutics buyer in Q1 2015 was Lansdowne Partners (UK), an estimated $10.5M added.

Based on aggregated 13F filings for Q1 2015.